^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gotistobart (BNT316) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ONCOC4 ANNOUNCES FAST TRACK DESIGNATION GRANTED BY THE U.S. FDA FOR ONC-392 MONOTHERAPY IN PD(L)1-RESISTANT NSCLC
Published date:
04/26/2022
Excerpt:
OncoC4, Inc....announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ONC-392, the Company’s next-gen anti-CTLA-4 monoclonal antibody (mAb) that preserves the CTLA-4 immune checkpoint function, as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.
